Versiti provides innovative diagnostic and prognostic testing in blood cancers to support patient stratification and therapeutic decisions. We deliver novel testing services that provide critical clinical direction in complex cases of acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and chronic myelogenous leukemia (CML). Our testing menus are built around testing algorithms as recommended by the National Comprehensive Cancer Network (NCCN) and the World Health Organization (WHO).